ENDRA Life Sciences Inc. (NDRA): Nasdaq/NYSE listing notice — ENDRA Life Sciences receives Nasdaq delisting notice for insufficient stockholders' equity
ENDRA Life Sciences Inc.
Stockholders' equity of $1,752,885 as of March 31, 2025, below Nasdaq's $2.5M minimum.
Nasdaq letter received May 27, 2025; company has until July 11, 2025 to submit a compliance plan.
If plan accepted, company has until November 23, 2025 to regain compliance.
Failure could lead to delisting; company intends to take measures to regain compliance, but no assurance given.
ENDRA Life Sciences Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
Exchange
nasdaq
Notice
deficiency notice
Deficiency
stockholders equity
Rules
5550(b)(1)
Exact text from the filing
May 27, 2025, ENDRA Life Sciences Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, because the Company’s stockholders’ equity as reported in its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 was $1,752,885, the Company is no longer in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on The Nasdaq Capital Market to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing. Nasdaq’s letter has no immediate impact on the listing of the Company’s common stock, which will cont
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.